Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221474 · ClinicalTrials.gov registry record · Phase 2
A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
A Phase 2 study of Squamous Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07221474: Recruiting Phase 2 study of Squamous Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.
NCT07221474 is a Phase 2 study of Squamous Non-Small Cell Lung Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 180 participants, below the 230-participant average among 6 other Squamous Non-Small Cell Lung Cancer trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221474, a Phase 2 study of Squamous Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to know if V940 (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). V940 is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive V940 with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.
Primary Outcome
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independ
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL V940
- DRUG Nab-paclitaxel
Study Locations (20)
Other
- Asan Medical Center ( Site 0503) - Seoul
- Samsung Medical Center ( Site 0502) - Seoul
- National Cheng Kung University Hospital ( Site 0601) - Tainan
- Mackay Memorial Hospital ( Site 0604) - Taipei
Buenos Aires
- Instituto Alexander Fleming ( Site 0201) - Ciudad Autonoma de Buenos Aires
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205) - Mar del Plata
Santa Fe Province
- Fundacion Estudios Clinicos ( Site 0207) - Rosario
- Sanatorio Parque ( Site 0203) - Rosario
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 0307) - Santiago
- Bradfordhill ( Site 0301) - Santiago
Kyonggi-do
- National Cancer Center ( Site 0504) - Goyang-si
- Seoul National University Bundang Hospital ( Site 0500) - Seongnam-si
New Jersey
- Valley Health Systems - Ridgewood Campus ( Site 0010) - Paramus
Ohio
- Cleveland Clinic - Ohio ( Site 0016) - Cleveland
Tennessee
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000) - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2031-05-06 |
| Phase | Phase 2 |
What NCT07221474 shows while recruiting
NCT07221474 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 230-participant average among 6 other Squamous Non-Small Cell Lung Cancer trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Squamous Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07221474 names 20 study sites across 13 states, led by Other, Buenos Aires, Santa Fe Province.
Frequently Asked Questions
What is clinical trial NCT07221474 about?
NCT07221474 is a clinical study titled "A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)". Researchers want to know if V940 (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). V940 is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if pe...
What is the current status of trial NCT07221474?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-12-12. Estimated completion is 2031-05-06.
What conditions does trial NCT07221474 study?
This clinical trial studies the following conditions: Squamous Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT07221474?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Paclitaxel (DRUG), V940 (BIOLOGICAL), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT07221474?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221474 being conducted?
This trial has 20 study locations across New Jersey, Ohio, Tennessee, Virginia, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RECRUITING · Phase 1
-
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI